IL-33 ameliorates Alzheimer's-like pathology and cognitive decline

Hong Kong University of Science and Technology recently conducted a study on the potential therapeutic role of interleukin-33 (IL-33) in AD, where they injected the protein into transgenic mouse models of AD. The injection of IL-33 rescues contextual memory deficits and reduces the deposition of β-amyloid peptide in the transgenic mouse model, suggesting that IL-33 can be developed as a new therapeutic intervention for AD.
Go to Source